Molecular Insights and Therapeutic Targets for Diabetic Endothelial Dysfunction
Top Cited Papers
- 29 September 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 120 (13), 1266-1286
- https://doi.org/10.1161/circulationaha.108.835223
Abstract
No abstract availableKeywords
This publication has 253 references indexed in Scilit:
- AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activityNature, 2009
- Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthaseCardiovascular Research, 2009
- Reactive Nitrogen Species Is Required for the Activation of the AMP-activated Protein Kinase by Statin in VivoJournal of Biological Chemistry, 2008
- AMP‐ACTIVATED PROTEIN KINASE ACTIVATION AS A STRATEGY FOR PROTECTING VASCULAR ENDOTHELIAL FUNCTIONClinical and Experimental Pharmacology and Physiology, 2007
- AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1αProceedings of the National Academy of Sciences, 2007
- AMP-activated protein kinase mediates VEGF-stimulated endothelial NO productionBiochemical and Biophysical Research Communications, 2007
- Peroxynitrite and protein tyrosine nitration of prostacyclin synthaseProstaglandins & Other Lipid Mediators, 2007
- Role of AMP-activated protein kinase in mechanism of metformin actionJournal of Clinical Investigation, 2001
- Evaluation of the mechanism of endothelial dysfunction in the genetically-diabetic BB ratLife Sciences, 1996
- Effect of insulin treatment on prostacyclin in experimental diabetesDiabetologia, 1980